<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="7069">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00959751</url>
  </required_header>
  <id_info>
    <org_study_id>NXN-188-204</org_study_id>
    <nct_id>NCT00959751</nct_id>
  </id_info>
  <brief_title>Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura</brief_title>
  <official_title>Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN-188 for the Treatment of Moderate to Severe Migraine Headache Without Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeurAxon Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeurAxon Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a a multi-center, randomized, double-blind, parallel group, and placebo controlled,
      two-arm study of a single oral dose of NXN-188 for the treatment of acute migraine headache
      without aura. Up to 120 migraineurs will be enrolled. Approximately 60 subjects having a
      headache history of migraine without aura will complete each of the two treatment arms to
      evaluate NXN-188 600 mg or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After study eligibility was confirmed and all screening procedures completed, subjects were
      randomized at Visit 1 to receive either NXN-188 600 mg or placebo in a 1:1 ratio. Study drug
      and diaries were dispensed, and subjects were instructed regarding when to dose with study
      drug. Subjects were also trained regarding the Interactive Voice Response System (IVRS), and
      made familiar with the study diary and the completion of study diary assessments. Subjects
      left the clinic to self-administer treatment as an outpatient at the onset of a moderate to
      severe migraine headache without aura (as rated on a 4-point categorical scale). Dosing with
      study drug was to take place within 42 days from Randomization (Visit 1). The subject
      contacted the investigatorI or designee at 14 and 28 days after Randomization if they had
      not yet treated a migraine headache without aura in order to receive verbal permission from
      the site personnel to continue in the study as appropriate. If the subject had not treated a
      migraine headache within 42 days of Visit 1, the subject did not take study drug and
      returned all materials, including the unused study drug, to the study site. If the subject
      experienced a qualifying migraine without aura during the treatment period, (s)he recorded
      headache symptoms in the study diary when first noticed (and menstrual cycle status [female
      subjects only]). If the subject met dosing requirements as outlined in the protocol, they
      dosed with the study drug, called the IVRS to report dosing, recorded all assessments and
      adverse events (AEs) and contacted the study center to schedule a post treatment visit
      (Visit 2) within 6 days (± 2 days) of treatment. If study drug resulted in insufficient
      relief at 2 hours p.a., subjects were permitted to use the non-triptan rescue medication
      recommended by the PI at Visit 1. Within 6 days (± 2 days) of treatment, the subject
      returned to the study center for Visit 2. The subject had a brief physical examination, a
      12-lead electrocardiogram (ECG), and had samples taken for clinical laboratory tests,
      including a serum pregnancy test for all females. Concomitant medications taken and adverse
      events (AEs) experienced from time of dosing to Visit 2 were reported to site personnel and
      recorded. Study diaries were reviewed and information recorded. Discontinuing subjects
      returned unused study drug and study material. One safety follow-up telephone contact was
      made within 15 days (± 2 days) post treatment. For those subjects not meeting the
      Treatment/Enrollment criteria by Day 42 (i.e., not experiencing a qualifying headache) and
      for other subjects discontinuing the study protocol post Randomization (Visit 1), a second
      visit, Visit 2, was required and subjects underwent a brief physical examination, had vital
      signs and ECGs performed, samples collected for clinical labs, concomitant medications and
      AEs reviewed, and returned all study drug and study materials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Headache Relief (Modified LOCF - Efficacy Evaluable Analysis Set)</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Headache relief at 2 hours post administration defined as reduction from Baseline moderate or severe score to mild or none.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Headache Recurrence (Modified LOCF - Efficacy Evaluable Analysis Set)</measure>
    <time_frame>4 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Headache recurrence is defined as any subject that experiences headache relief at the given time point (i.e., 2 hours or 4 hours), who did not use rescue medication and who experienced a worsening of their headache to moderate or severe within 24 hours following study drug administration. The denominator is the number of subjects who experienced headache relief at 2 hours/4 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache Relief Based on a 2-Point Reduction From Baseline (Modified LOCF - Efficacy Evaluable Analysis Set)</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Headache Severity Score (HSS) assessment was recorded in the diary by the subject and used the following categories: 0 = no pain; 1 = mild pain; 2 = moderate pain; and, 3 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Headache Relief Based on a 1-Point Reduction From Baseline (Modified LOCF - Efficacy Evaluable Analysis Set)</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>The Headache Severity Score (HSS) assessment was recorded in the diary by the subject and used the following categories: 0 = no pain; 1 = mild pain; 2 = moderate pain; and, 3 = severe pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Headache Relief (Efficacy Evaluable Analysis Set)</measure>
    <time_frame>72 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (Hours) to First Use of Rescue Medication (Full Analysis Set)</measure>
    <time_frame>24 Hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects who do not require rescue medication are censored at the time of their last diary assessment completed up to 24 hours following study drug administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Evaluation of Study Medication at 24 Hours Post Administration (Full Analysis Set)</measure>
    <time_frame>24 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Overall evaluation of the study drug was measured with a 4-point scale at 24 hours and used the following categories: 1 = Poor; 2 = Moderate; 3 = Good; and,4 = Excellent</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Migraine Without Aura</condition>
  <arm_group>
    <arm_group_label>NXN-188 600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 x 200 mg capsules, PRN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 x 0 mg capsules, PRN</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NXN-188</intervention_name>
    <description>200 mg capsules, 600 mg, PRN</description>
    <arm_group_label>NXN-188 600 mg</arm_group_label>
    <other_name>NXN-188 dihydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>200 mg capsules with no active ingredient designed to match the NXN-188 capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Meets the following criteria for migraine headache without aura: Previously diagnosed
             with a history of migraine headaches; Headache has at least two (2) of the following
             characteristics: Unilateral location; Pulsating quality; Moderate or severe pain
             intensity; Aggravation by routine physical activity such as walking or climbing
             stairs; During headache, has at least one of the following characteristics: Nausea
             and/or vomiting; Photophobia and/or phonophobia;Not attributable to another disorder

          2. Headache frequency of at least 2 migraine attacks per month for the past 3 months but
             not more than 8 migraines in any 30 day period. Each migraine attack should last at
             least 4 hours (without treatment) and not longer than 72 hours.

          3. At the time of the study migraine, prior to dosing with study medication, the
             headache severity, as judged and documented by the subject, is either moderate or
             severe

          4. BMI within the range of 18 to 35

          5. Good general health as determined by the medical history, physical exam, clinical
             laboratory tests, vital signs and electrocardiogram. ALT cannot be above 1.5x upper
             limit of normal; creatinine and urea must be within normal limits

          6. Speak, read, and understand English or French, sufficiently to understand the nature
             of the study, to provide written informed consent, and complete all study
             assessments.

          7. Willing and able to comply with all testing requirements defined in the protocol

          8. Females will avoid pregnancy at least 10 days before randomization, during the study
             and up until 3 months after treatment

          9. All subjects/partners must use a double-barrier method of birth control during the
             study and for 3 months after dosing (female subjects who have had a tubal ligation &gt;
             1 year or who are post menopausal or post hysterectomy &gt; 1 year and male subjects who
             are surgically sterile are exempted from this inclusion criteria.

        Exclusion Criteria:

        A diagnosis of headaches that is not consistent with migraine without aura as defined in
        the inclusion criteria. Subjects with a history of migraine with aura are excluded.

          1. Presence of any risk factors that would preclude the use of triptans: Uncontrolled
             hypertension; Ischemic heart disease; Prinzmetal angina; Cardiac arrhythmias;
             Multiple risk factors for ischemic atherosclerotic vascular disease; Primary
             vasculopathies; Basilar and hemiplegic migraine

          2. Known allergy or hypersensitivity to triptans or history of any serious side effect
             with a triptan which would preclude further dosing with a triptan

          3. Presence of any clinically significant condition that would preclude study
             participation, as evaluated by the investigator

          4. Pregnant or lactating

          5. History of significant neurological, hepatic, renal, endocrine, cardiovascular,
             gastrointestinal, pulmonary, rheumatologic, autoimmune, or metabolic disease

          6. Any use (within 30 days of randomization) of migraine prevention medication
             including: Valproate (Depakote), topiramate (Topamax), cyproheptadine (Periactin),
             montelukast (Singulair), or botulinum toxin, type A (Botox); Cardiovascular drugs
             (acceptable if reason for use is for treatment of cardiovascular disease and the
             subject has been on a stable dose; MAOIs within 30 days of randomization

          7. Initiation of therapy with SSRIs or SNRIs for depression or other approved indication
             within 90 days of randomization (subjects on stable dose for &gt;3 months for treatment
             of depression or other approved indication may be included)

          8. Are known to or suspected to be currently abusing alcohol or drugs, or have a history
             (within the past 12 months) of active alcohol or drug abuse

          9. Participation in another drug or biologic study within 30 days of randomization into
             this study or during participation in this study

         10. Subjects unable or unwilling, in the opinion of the Investigator, to comply with all
             study procedures and cooperate fully with study center staff
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guy Boudreau, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Notre-Dame Du Chum, Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Comprehensive Neuroscience, Inc.</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience, Inc. Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elkind Headache Center</name>
      <address>
        <city>Mount Vernon</city>
        <state>New York</state>
        <zip>10550</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <lastchanged_date>July 12, 2014</lastchanged_date>
  <firstreceived_date>August 14, 2009</firstreceived_date>
  <firstreceived_results_date>May 8, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>migraine</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study Period - 6 months. First subject screened 28 July 2009, Last subject completed the study 9 February 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>3 x capsules, PRN</description>
        </group>
        <group group_id="P2">
          <title>NXN-188 600 mg</title>
          <description>3 x 200 mg capsules, PRN</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance to Study Procedures</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No migraine headache without aura</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Of the 195 subjects randomized, 174 subjects received study drug: the 174 subjects constitute the Safety Population.</population>
      <group_list>
        <group group_id="B1">
          <title>NXN-188</title>
          <description>3 x 200 mg capsules</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>3 x 0 mg capsules</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
                <measurement group_id="B2" value="88"/>
                <measurement group_id="B3" value="174"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40.2" spread="12.34"/>
                <measurement group_id="B2" value="38.4" spread="12.63"/>
                <measurement group_id="B3" value="39.3" spread="12.49"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
                <measurement group_id="B2" value="74"/>
                <measurement group_id="B3" value="140"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="65"/>
                <measurement group_id="B2" value="75"/>
                <measurement group_id="B3" value="140"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="32"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="72"/>
                <measurement group_id="B2" value="66"/>
                <measurement group_id="B3" value="138"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="3"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="74.94" spread="14.695"/>
                <measurement group_id="B2" value="74.74" spread="17.066"/>
                <measurement group_id="B3" value="74.84" spread="15.893"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="168.33" spread="8.502"/>
                <measurement group_id="B2" value="165.91" spread="9.960"/>
                <measurement group_id="B3" value="167.10" spread="9.321"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="26.2" spread="4.09"/>
                <measurement group_id="B2" value="27.2" spread="5.28"/>
                <measurement group_id="B3" value="26.7" spread="4.74"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Type of Migraine</title>
          <description>Subjects are counted once within each type where at least one migraine is recorded.</description>
          <units>Participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Without Aura</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="86"/>
                <measurement group_id="B2" value="88"/>
                <measurement group_id="B3" value="174"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>With Aura</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Number of Previous Migraines</title>
          <description>Previous Migraines for each subject was based on the total number of migraine entries reported on the Migraine History CRF</description>
          <units>migraine episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="1.1" spread="0.30"/>
                <measurement group_id="B2" value="1.1" spread="0.23"/>
                <measurement group_id="B3" value="1.1" spread="0.27"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Headache Relief (Modified LOCF - Efficacy Evaluable Analysis Set)</title>
        <description>Headache relief at 2 hours post administration defined as reduction from Baseline moderate or severe score to mild or none.</description>
        <time_frame>2 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Modified LOCF - Efficacy Evaluable Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules, PRN</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 x 0 mg capsules, PRN</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Headache Relief (Modified LOCF - Efficacy Evaluable Analysis Set)</title>
            <description>Headache relief at 2 hours post administration defined as reduction from Baseline moderate or severe score to mild or none.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="30"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Relief Based on a 2-Point Reduction From Baseline (Modified LOCF - Efficacy Evaluable Analysis Set)</title>
        <description>The Headache Severity Score (HSS) assessment was recorded in the diary by the subject and used the following categories: 0 = no pain; 1 = mild pain; 2 = moderate pain; and, 3 = severe pain</description>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules, PRN</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 x 0 mg capsules, PRN</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Headache Relief Based on a 2-Point Reduction From Baseline (Modified LOCF - Efficacy Evaluable Analysis Set)</title>
            <description>The Headache Severity Score (HSS) assessment was recorded in the diary by the subject and used the following categories: 0 = no pain; 1 = mild pain; 2 = moderate pain; and, 3 = severe pain</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Headache Relief - 2 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="17"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache Relief - 4 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="45"/>
                  <measurement group_id="O2" value="26"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache Relief - 24 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                  <measurement group_id="O2" value="42"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache Relief - 72 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Headache Relief Based on a 1-Point Reduction From Baseline (Modified LOCF - Efficacy Evaluable Analysis Set)</title>
        <description>The Headache Severity Score (HSS) assessment was recorded in the diary by the subject and used the following categories: 0 = no pain; 1 = mild pain; 2 = moderate pain; and, 3 = severe pain</description>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules, PRN</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 x 0 mg capsules, PRN</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Headache Relief Based on a 1-Point Reduction From Baseline (Modified LOCF - Efficacy Evaluable Analysis Set)</title>
            <description>The Headache Severity Score (HSS) assessment was recorded in the diary by the subject and used the following categories: 0 = no pain; 1 = mild pain; 2 = moderate pain; and, 3 = severe pain</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Headache Relief - 2 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="40"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache Relief - 4 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="63"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache Relief - 24 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="64"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache Relief - 72 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="62"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Headache Relief (Efficacy Evaluable Analysis Set)</title>
        <time_frame>72 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules, PRN</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 x 0 mg capsules, PRN</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Complete Headache Relief (Efficacy Evaluable Analysis Set)</title>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Complete Headache Relief - 2 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Complete Headache Relief - 4 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="35"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Complete Headache Relief - 24 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="36"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Complete Headache Relief - 72 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="54"/>
                  <measurement group_id="O2" value="43"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Headache Recurrence (Modified LOCF - Efficacy Evaluable Analysis Set)</title>
        <description>Headache recurrence is defined as any subject that experiences headache relief at the given time point (i.e., 2 hours or 4 hours), who did not use rescue medication and who experienced a worsening of their headache to moderate or severe within 24 hours following study drug administration. The denominator is the number of subjects who experienced headache relief at 2 hours/4 hours.</description>
        <time_frame>4 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>30 and 42 placebo and NXN-188 subjects, respectivley, experienced headache relief at 2 hours. 41 and 55 placebo and NXN-188 subjects, respectively, experienced headache relief at 4 hours.</population>
        <group_list>
          <group group_id="O1">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules, PRN</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 x 0 mg capsules, PRN</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Headache Recurrence (Modified LOCF - Efficacy Evaluable Analysis Set)</title>
            <description>Headache recurrence is defined as any subject that experiences headache relief at the given time point (i.e., 2 hours or 4 hours), who did not use rescue medication and who experienced a worsening of their headache to moderate or severe within 24 hours following study drug administration. The denominator is the number of subjects who experienced headache relief at 2 hours/4 hours.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Headache Recurrence - 2 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3"/>
                  <measurement group_id="O2" value="6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Headache Recurrence - 4 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2"/>
                  <measurement group_id="O2" value="4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time (Hours) to First Use of Rescue Medication (Full Analysis Set)</title>
        <description>Subjects who do not require rescue medication are censored at the time of their last diary assessment completed up to 24 hours following study drug administration.</description>
        <time_frame>24 Hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects in the Safety Population who had at least one post-dose observation for headache severity recorded in his or her diary.</population>
        <group_list>
          <group group_id="O1">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules, PRN</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 x 0 mg capsules, PRN</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                  <measurement group_id="O2" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Time (Hours) to First Use of Rescue Medication (Full Analysis Set)</title>
            <description>Subjects who do not require rescue medication are censored at the time of their last diary assessment completed up to 24 hours following study drug administration.</description>
            <units>Participants who required rescue</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="NA">Median times not estimable by Kaplan-Meier because too few subjects required rescue medication within 25 hrs</measurement>
                  <measurement group_id="O2" value="NA" lower_limit="19.6">Median times not estimable by Kaplan-Meier because too few subjects required rescue medication within 24 hrs</measurement>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Evaluation of Study Medication at 24 Hours Post Administration (Full Analysis Set)</title>
        <description>Overall evaluation of the study drug was measured with a 4-point scale at 24 hours and used the following categories: 1 = Poor; 2 = Moderate; 3 = Good; and,4 = Excellent</description>
        <time_frame>24 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Full Analysis Set includes all subjects in the Safety Population who had at least one post-dose observation for headache severity recorded in his or her diary.</population>
        <group_list>
          <group group_id="O1">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules, PRN</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 x 0 mg capsules, PRN</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                  <measurement group_id="O2" value="88"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Overall Evaluation of Study Medication at 24 Hours Post Administration (Full Analysis Set)</title>
            <description>Overall evaluation of the study drug was measured with a 4-point scale at 24 hours and used the following categories: 1 = Poor; 2 = Moderate; 3 = Good; and,4 = Excellent</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>1 = Poor</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="37"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2 = Moderate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="22"/>
                  <measurement group_id="O2" value="19"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>3 = Good</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="21"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4 = Excellent</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="11"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Sustained Complete Headache Relief (Efficacy Evaluable Analysis Set)</title>
        <description>Exploratory Post-hoc Analysis: Sustained complete headache relief is defined as a reduction in headache severity from moderate or severe to absent over all indicated time points.</description>
        <time_frame>2 - 48 hours</time_frame>
        <safety_issue>No</safety_issue>
        <population>Efficacy Evaluable Analysis Set includes all subjects in the Full Analysis Set with an observed or imputed HSS (using rules predefined in the Statistical Analysis Plan [SAP]) at both the 2-hour time point and the 4-hour time point when using the modified LOCF approach</population>
        <group_list>
          <group group_id="O1">
            <title>NXN-188 600 mg</title>
            <description>3 x 200 mg capsules, PRN</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>3 x 0 mg capsules, PRN</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="80"/>
                  <measurement group_id="O2" value="79"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Sustained Complete Headache Relief (Efficacy Evaluable Analysis Set)</title>
            <description>Exploratory Post-hoc Analysis: Sustained complete headache relief is defined as a reduction in headache severity from moderate or severe to absent over all indicated time points.</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>2-24 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4-24 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="32"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>2-48 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>4-48 hours</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected throughout the study beginning with the dosing of study drug and ending 15 days (± 2 days) p.a.</time_frame>
      <desc>All AE summaries were restricted to TEAEs, which were defined as those AEs that occurred after dosing and those existing AEs that worsened during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>NXN-188 600 mg</title>
          <description>3 x 200 mg capsules, PRN</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>3 x 0 mg capsules, PRN</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="86"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="86"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sensation of heaviness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="86"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="88"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="86"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="86"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="88"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor may request Investigator or Institution not to publish or disclose information related to the clinical study.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Lategan, PhD</name_or_title>
      <organization>NeurAxon, Inc.</organization>
      <phone>417-673-6697</phone>
      <email>tlategan@neuraxon.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
